Back to Awarded Treatment Trials
Awarded Trial: BPN-2
Grant ID
BPN-2
Illness
Bipolar Disorder
Primary Drug/Intervention
Ethyl Eicosapentanoic Acid
Primary Dosage
6 grams/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Keck
Sample Size
121
Duration of Study Period for Each Subject
4 weeks
Outcome Measurements
Inventory of Depressive Symptoms, CGI-BP
Results
Fifty nine subjects with bipolar depression and 62 subjects with rapid cycling bipolar disorder were randomized to receive 6 grams per day of ethyl-eicosapentanoic acid (EPA) or placebo adjunctive to mood stabilizers for 4 months. There was no significant difference betwen EPA or placebo for rating of depression (Inventory of Depressive Symptoms) or rapid cycling (CGI-BP).
Publication
Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM. Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder. Biol Psychiatry. 2006 Nov 1;60(9):1020-2.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16814257
PI Name
Paul Keck
Degree
MD
Center
N/A
Institution
University of Cincinnati College of Medicine
Address
231 Albert Sabin Way
City or Town
Cincinnati
State or Province
OH
Zip or Postal Code
45267
Country
USA
Email Address
KECKPE@UCMAIL.UC.EDU